These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 38436784)
1. Updates on Non-Statin LDL-Lowering Therapy. Abdulla A; Shalaby M; Kumfa P; Raja M; Allencherril J; Sharifeh TA Curr Cardiol Rep; 2024 Apr; 26(4):221-231. PubMed ID: 38436784 [TBL] [Abstract][Full Text] [Related]
2. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965 [TBL] [Abstract][Full Text] [Related]
3. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377 [TBL] [Abstract][Full Text] [Related]
4. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function. Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498 [TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
6. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go? Qamar A; Libby P Curr Cardiol Rep; 2019 Jun; 21(8):77. PubMed ID: 31250329 [TBL] [Abstract][Full Text] [Related]
12. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
13. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491 [TBL] [Abstract][Full Text] [Related]
14. Inclisiran: A Review in Hypercholesterolemia. Frampton JE Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996 [TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955 [TBL] [Abstract][Full Text] [Related]
16. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949 [TBL] [Abstract][Full Text] [Related]
17. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD; Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077 [TBL] [Abstract][Full Text] [Related]
18. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. O'Keefe JH; DiNicolantonio JJ; Lavie CJ Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940 [TBL] [Abstract][Full Text] [Related]
19. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Adhyaru BB; Jacobson TA Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Tomlinson B; Chan P; Zhang Y; Lam CWK Expert Opin Pharmacother; 2020 Dec; 21(17):2137-2151. PubMed ID: 32772741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]